Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 4/20 | 0.48 |
| ▸ | TYMP | P19971 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.40 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | RPA1 | P27694 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8080258 | 0.81 | ALDH1A1 (0.36) | DHFRTYMPNR3C1TYMSKDM4E | |
| SCHEMBL6086721 | 0.81 | TYMP (0.37) | DHFRTYMPNR3C1KDM4EALDH1A1 | |
| SCHEMBL7104065 | 0.79 | KDM4E (0.39) | DHFRTYMPTYMSKDM4EALDH1A1 | |
| SCHEMBL7070893 | 0.75 | DHFR (0.47) | DHFRTYMPTYMSKDM4EALDH1A1 | |
| SCHEMBL5197218 | 0.70 | TYMP (0.57) | TYMPNR3C1KDM4EALDH1A1 | |
| SCHEMBL9009417 | 0.69 | LMNA (0.47) | DHFRKDM4EALDH1A1POLB | |
| SCHEMBL9009424 | 0.69 | DHFR (0.39) | DHFRALDH1A1 | |
| SCHEMBL8582935 | 0.69 | TYMP (0.45) | DHFRTYMPKDM4EALDH1A1HSD17B10 | |
| SCHEMBL4130012 | 0.69 | TYMP (0.41) | TYMPNR3C1KDM4EALDH1A1POLB | |
| SCHEMBL10857095 | 0.69 | TYMP (0.59) | TYMPNR3C1KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0639971-A1 | THERAPEUTIC COMBINATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-03-01 | — | — | EP | claimed |
| WO-1993023021-A2 | THERAPEUTIC COMBINATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-11-25 | — | — | WO | claimed |
| US-6841555-B2 | Lavendamycin analogs, quinoline-5,8-diones and methods of using them | BALL STATE UNIVERSITY (US) | 2005-01-11 | — | — | US | disclosed |
| US-20040248922-A1 | LAVENDAMYCIN ANALOGS, QUINOLINE-5,8-DIONES AND METHODS OF USING THEM | BALL STATE UNIVERSITY | 2004-12-09 | — | — | US | disclosed |
| US-6444684-B1 | ANTIBIOTIC AND ANTI-HIV REVERSE TRANSCRIPTASE (HIV-RT) ACTIVITY; TREATING HIV INFECTION AND ALSO WITH AZT; ANTITUMOR | BALL STATE UNIVERSITY | 2002-09-03 | — | — | US | disclosed |
| EP-0736015-B1 | ANTIVIRAL 2,4-PYRIMIDINDIONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | KOREA RES INST CHEM TECH (KR) | 2001-03-07 | — | — | EP | disclosed |
| US-6177435-B1 | DETECTING ZIDOVUDINE RESISTANCE; ADMINISTERING 2',3'-DIDEOXY-5-FLUORO-3'-THIACYTIDINE; ALTERNATING DRUG CYCLES | GLAXO WELLCOME INC. | 2001-01-23 | — | — | US | disclosed |
| US-6030983-A | ANTITUMOR AND -CARCINOGENIC AGENTS; ANTIBIOTICS; BACTERICIDES; VIRICIDES; PARACITICIDES; ENZYME INHIBITORS; POLYMERASES; FARNESYL-PROTEIN TRANSFERASE; RAS PROTEINS | BALL STATE UNIVERSITY (US) | 2000-02-29 | — | — | US | disclosed |
| US-5922727-A | 1-((SUBSTITUTED)CYCLOALK(EN)YLALKYL)-6-((SUB)PHENYL(CARBONYL, SULFIDE, OR OXO))-2,4-PYRIMIDINEDIONE DERIVATIVES HAVING SUPERIOR ANTIVIRAL ACTIVITIES; HIV | SAMJIN PHARMACEUTICAL CO., LTD (KR) | 1999-07-13 | — | — | US | disclosed |
| EP-0914824-A1 | PREVENTIVE AND REMEDY FOR VIRAL INFECTIONS | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1999-05-12 | — | — | EP | disclosed |
| US-5747500-A | VIRICIDES FOR AIDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1998-05-05 | — | — | US | disclosed |
| US-5733904-A | USING A SULFONAMIDE CONTAINING ISOQUINOLINE COMPOUND | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1998-03-31 | — | — | US | disclosed |
| EP-0827498-A1 | NEW ANTIVIRAL SUBSTITUTED PYRIMIDINEDIONE HOMOCARBOCYCLIC NUCLEOSIDE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENTS | Samjin Pharmaceutical Co., Ltd. (KR) | 1998-03-11 | — | — | EP | disclosed |
| WO-1997030979-A1 | NEW ANTIVIRAL SUBSTITUTED PYRIMIDINEDIONE HOMOCARBOCYCLIC NUCLEOSIDE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENTS | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 1997-08-28 | — | — | WO | disclosed |
| EP-0736015-A1 | NOVEL ANTIVIRAL 2,4-PYRIMIDINEDIONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995018109-A1 | NOVEL ANTIVIRAL 2,4-PYRIMIDINEDIONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1995-07-06 | — | — | WO | disclosed |
| EP-0639971-A1 | THERAPEUTIC COMBINATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993023021-A2 | THERAPEUTIC COMBINATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248922-A1 | LAVENDAMYCIN ANALOGS, QUINOLINE-5,8-DIONES AND METHODS OF USING THEM | LSS, CYP51A1, COX5A | DHFR 245/4885TYMP 1115/4885NR3C1 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.